MTVA · MetaVia Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about our ability to continue as a going concern within one year from the issuance of these unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 6, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Dec 5, 2025; bars on opposite sides are not compared.
The closing range begins at the captured split on Dec 5, 2025.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MTVA
this stock
MetaVia Inc.
|
$9.82M | -82.4% | — | — | 2.4% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +19.3% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +13.7% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.4% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +17.5% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Dec 5, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MTVA | +3.5% | -11.9% | -7.5% | +4.2% | -82.4% |
| SPY | -0.1% | +4.1% | +12.4% | +3.4% | +13.3% |
| vs SPY | +3.6% | -16.0% | -19.9% | +0.8% | -95.7% |